Drug intelligence / Profile preview

WXSH0408

Development stage: Unknown
Lead developer: Zhikang Hongren
Modality: Small Molecules
Administration: Oral

Overview

WXSH0408 is an orally administered small molecule drug under development by Shijiazhuang Sagacity New Drug Development for the treatment of psoriasis. It is part of a new generation of targeted therapies in China focused on treating psoriasis and potentially other inflammatory conditions. The drug's mechanism involves inhibition of Tyrosine kinase 2 (TYK2), a member of the Janus kinase family implicated in immune signaling pathways relevant to autoimmune diseases such as psoriasis[1][10]. Clinical development has reached at least Phase III trials for psoriasis.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on WXSH0408.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXSH0408.

Explore the full profile